The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.
Highly recommended - Individuals: transactions
Household-name multinationals – particularly in the life sciences – flock to the doors of Stephenson Harwood. It has its boots on the ground in almost every continent and by coordinating with its sister offices and collaborating with its high-profile clients, the team finds pragmatic solutions to complex multi-jurisdictional skirmishes. For example, one of its most recent and notable highlights includes its recent implementation of a worldwide litigation programme for GlaxoSmithKline against Sandoz and Glenmark Pharmaceuticals. Its IP transactions practice is especially potent – not least thanks to the efforts of chemist Alexandra Pygall, who is also a polished litigator. She “never fails to deliver extremely high-quality work product and is utterly brilliant with clients, navigating the sometimes difficult line of providing practical, no-nonsense advice while addressing business-sensitive topics”. Pygall has lately been assisting Oxford Biomedica with a range of IP-related contracts, licensing agreements and other arrangements in relation to the AstraZeneca covid-19 vaccine, for which her client is a key manufacturing partner. Working alongside her on this is fellow life sciences expert Naomi Leach, who consistently gets transformative collaboration and patent licensing agreements, as well as IP-related M&A deals, across the line. Litigation and transactions are the twin focuses of Rob Jacob, “one of the most effective IP lawyers out there”; he recently acted for Eureka Shipping in a High Court dispute which led to changes in licensing laws around the sale of damaged products. Guiding the whole operation is chief executive Eifion Morris, who built the IP group from the ground up and now steers the global strategy of the firm’s entire corporate offering.